Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
OY Arctic Partners AB is currently active in the Biotechnology & Pharmaceuticals technology area, with 1 pending office action on file. This activity represents the company's current efforts to protect its biological or pharmaceutical innovations. Navigating the complex requirements of the Biotechnology & Pharmaceuticals sector is a key part of the company's intellectual property strategy as it moves through the prosecution phase.
The portfolio's pending matters are reviewed by 1 distinct examiner and are located within 1 distinct art unit. This concentration indicates that the technical scope of the applications is specialized enough to be handled by a single administrative group. For the applicant, this means that the prosecution strategy can be tailored to the specific standards of 1 distinct art unit. This focused approach can lead to a more predictable examination experience for the 1 distinct examiner assigned.
LU, FRANK WEI MIN is the busiest examiner for this portfolio, currently managing 1 busiest examiner pending office action. As the only examiner with a pending matter, LU, FRANK WEI MIN holds a central role in determining the outcome of the company's current patent applications. Practitioners should monitor the specific examination tendencies of this official to effectively address the 1 busiest examiner pending office action. This centralized review structure allows for direct communication with the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, FRANK WEI MIN | 1 | 62.7% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793960 | Luminescence hybridisation assay method | LU, FRANK WEI MIN | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793960 | Luminescence hybridisation assay method | LU, FRANK WEI MIN | 34d |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17793960 | Luminescence hybridisation assay method | LU, FRANK WEI MIN | 1683 | §103§112 | Final Rejection | 34d | Pending | Jul 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial